Hot Watch List: Microsoft Corporation (NASDAQ:MSFT), Actua Corporation (NASDAQ:ACTA), General Electric Company (NYSE:GE), Parker Drilling Co. (NYSE:PKD), HSBC Holdings plc (ADR) (NYSE:HSBC)

Microsoft Corporation (NASDAQ:MSFT) has 3.00% insider ownership while its institutional ownership stands at 73.90%. In last trading activity company’s stock closed at $46.70. Microsoft Corp. (NASDAQ:MSFT) is evaluating a bid for Salesforce.com Inc., after the cloud software provider was approached by another would-be buyer, people with knowledge of the matter said.

Actua Corporation (NASDAQ:ACTA) in last trading activity moved up 5.19% to close at $13.79. Company weekly performance is -4.70% while its quarterly performance stands at -14.56%. Actua Corporation (NASDAQ:ACTA) is -34.98% away from its 52 week high. Actua Corporation
(NASDAQ:ACTA) on 5 May, reported its results for the first quarter ended March 31, 2015. Revenue was $30.6 million for the first quarter of 2015, up from $18.4 million for the first quarter of 2014. Net income (loss) attributable to Actua common shareholders for the first quarter of 2015 was $(14.8) million, or $(0.40) per diluted share, compared to net income (loss) of $(10.2) million, or $(0.27) per diluted share, for the comparable prior year quarter. Non-GAAP net income (loss) for the first quarter of 2015 was $(3.8) million, or $(0.10) per share, compared to a non-GAAP net income (loss) of $(3.6) million, or $(0.10) per diluted share, for the comparable prior year quarter. Cash flow from operations was a use of $(4.4) million for the first quarter of 2015, compared to a use of $(9.7) million for the comparable prior year quarter.

On last trading day General Electric Company (NYSE:GE) advanced 0.86% to close at $27.04. Its volatility for the week is 1.66% while volatility for the month is 1.94%. GE’s sales growth for past 5 years was -0.80% and its EPS growth for past 5 years was 8.80%. General Electric Company (NYSE:GE) monthly performance is 8.12%.General Electric Company (NYSE:GE) here agreed to a settlement of charges by the National Labor Relations Board that the company illegally interfered with free speech and labor rights of more than 1,000 workers at its diesel engine plants.

Parker Drilling Co. (NYSE:PKD) has 1.00% insider ownership while its institutional ownership stands at 73.10%. In last trading activity company’s stock closed at $3.64. Parker Drilling Co. (NYSE:PKD) on Tuesday reported first-quarter net income of $3.2 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Houston-based company said it had net income of 3 cents. The drilling contractor and oilfield services company posted revenue of $204.1 million in the period. In the final minutes of trading on Tuesday, the company’s shares hit $3.71. A year ago, they were trading at $6.61.

On last trading day HSBC Holdings plc (ADR) (NYSE:HSBC) decreased -0.15% to close at $48.18. Its volatility for the week is 0.95% while volatility for the month is 0.83%. HSBC’s sales growth for past 5 years was -3.90% and its EPS growth for past 5 years was 15.30%. HSBC Holdings plc (ADR) (NYSE:HSBC) monthly performance is 10.08%. HSBC Holdings plc (ADR) (NYSE:HSBC) had its “underperform” rating reaffirmed by analysts at Credit Suisse.

Biotechnology Top Losers: Regulus Therapeutics Inc. (NASDAQ:RGLS), Genetic Technologies Limited (NASDAQ:GENE), NanoString Technologies (NASDAQ:NSTG), MediciNova Inc. (NASDAQ:MNOV), Medgenics (NYSEMKT:MDGN)

Regulus Therapeutics Inc. (NASDAQ:RGLS), announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). On Monday shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) closed at $15.64. Company’s EPS growth for next 5 years is recorded as 39.60%.

On 28 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus to their at-risk patients in a systematic broad Genetic Technologies Ltd. (NASDAQ: GENE) fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. Genetic Technologies Limited (NASDAQ:GENE) in last trading activity moved down -6.84% to close at $3.68. Company weekly performance is 42.08% while its quarterly performance stands at 67.27%. Genetic Technologies Limited (NASDAQ:GENE) is -69.46% away from its 52 week high.

NanoString Technologies, Inc. (NASDAQ:NSTG), announced that its management is scheduled to present at the 2015 Leerink Global Healthcare Conference in New York. Brad Gray, President and Chief Executive Officer, is scheduled to present on Wednesday, February 11, 2015 at 8:25am ET.On last trading day NanoString Technologies, Inc. (NASDAQ:NSTG) moved down -5.48% to close at $12.77. Its volatility for the week is 5.26% while volatility for the month is 5.46%. NSTG’s sales growth for past 5 years was 81.40% and its EPS growth for past 5 years was 33.60%. NanoString Technologies, Inc. (NASDAQ:NSTG) monthly performance is -2.44%.

On 3 February, MediciNova, Inc., (NASDAQ:MNOV) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of NASH (nonalcoholic steatohepatitis). MediciNova Inc. (NASDAQ:MNOV) has 0.30% insider ownership while its institutional ownership stands at 9.80%. In last trading activity company’s stock closed at $4.00.

Medgenics, Inc. (NYSEMKT:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results. On last trading day Medgenics, Inc. (NYSEMKT:MDGN) moved down -5.66% to close at $7.00. Its volatility for the week is 6.81% while volatility for the month is 8.23%. MDGN’s EPS growth for past 5 years was 10.00%. Medgenics, Inc. (NYSEMKT:MDGN) monthly performance is 10.41%.

Biotechnology Top Gainers: Calithera Biosciences (NASDAQ:CALA), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), Coherus Biosciences (NASDAQ:CHRS), Trevena (NASDAQ:TRVN), Cellular Biomedicine Group (NASDAQ:CBMG)

On 30 January, Calithera Biosciences, Inc. (NASDAQ:CALA), announced the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford will be responsible for clinical development of CB-839, its lead oral product candidate in tumor metabolism, as well as subsequent clinical development programs. On Monday shares of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $18.18. Company’s EPS growth for next 5 years is recorded as 75.00%.

EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), announced that the Company is scheduled to present a corporate overview at the Leerink Global Healthcare Conference in New York City on Thursday, February 12, 2015 at 11:35 a.m. Eastern Time. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) in last trading activity increased 15.26% to close at $5.59. Company weekly performance is 11.80% while its quarterly performance stands at 16.46%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is -67.87% away from its 52 week high.

Coherus BioSciences, Inc. (NASDAQ:CHRS), announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. On last trading day Coherus Biosciences, Inc. (NASDAQ:CHRS) increased 12.91% to close at $32.36. Its volatility for the week is 14.21% while volatility for the month is 10.09%. CHRS’s EPS growth for past 5 years was -44.33%. Coherus Biosciences, Inc. (NASDAQ:CHRS) monthly performance is 51.78%.

Trevena, Inc. (NASDAQ: TRVN), announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. Trevena, Inc. (NASDAQ:TRVN) has 1.50% insider ownership while its institutional ownership stands at 76.40%. In last trading activity company’s stock closed at $5.35.

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced its acquisition of Chinese PLA General Hospital’s (“PLAGH”, Beijing, also known as “301 Hospital”) Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor’s (EGFR or HER1) Immuno-Oncology patents (all pending), and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. On last trading day Cellular Biomedicine Group Inc. (NASDAQ:CBMG) increased 10.85% to close at $23.40. Its volatility for the week is 10.87% while volatility for the month is 8.60%. CBMG’s EPS growth for past 5 years was -19.20%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) monthly performance is 55.90%.

Biotech Active Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naive genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $11.66. Company’s EPS growth for next 5 years is recorded as 17.58%.

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company’s Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors. The Board of Directors also approved the repurchase of up to an additional $15.0 billion of the company’s common stock. This new program is in addition to the currently authorized three-year $5.0 billion repurchase program (authorized in May 2014). Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity decreased -0.59% to close at $96.90. Company weekly performance is -8.75% while its quarterly performance stands at -9.39%. Gilead Sciences Inc. (NASDAQ:GILD) is -17.06% away from its 52 week high.

On 3 February, Sanofi and MannKind Corporation (NASDAQ:MNKD) announced that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. On last trading day MannKind Corp. (NASDAQ:MNKD) increased 7.75% to close at $7.51. Its volatility for the week is 6.21% while volatility for the month is 5.40%. MNKD’s EPS growth for past 5 years was 26.50%. MannKind Corp. (NASDAQ:MNKD) monthly performance is 29.93%.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has 1.90% insider ownership while its institutional ownership stands at 68.20%. In last trading activity company’s stock closed at $6.85.

Hot Biotech Movers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

On 3 February, Gilead Sciences, Inc. (NASDAQ:GILD) announced its results of operations for the fourth quarter and full year 2014. Total revenues for the fourth quarter of 2014 were $7.3 billion compared to $3.1 billion for the fourth quarter of 2013.On Friday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $97.48. Company’s sales growth for last 5 years was 16.00% and EPS growth for next 5 years is recorded as 33.42%.

Achillion Pharma (NASDAQ: ACHN) announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity fell -2.35% to close at $10.82. Company weekly performance is -27.14% while its quarterly performance stands at 6.60%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is -35.86% away from its 52 week high.

On 3 February, Sanofi and MannKind Corporation (NASDAQ:MNKD) announced that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. On last trading day MannKind Corp. (NASDAQ:MNKD) fell -1.83% to close at $6.97. Its volatility for the week is 5.25% while volatility for the month is 5.17%. MNKD’s EPS growth for past 5 years was 26.50%. MannKind Corp. (NASDAQ:MNKD) monthly performance is 23.36%.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will present at the Leerink Global Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Thursday, February 12, at 3:30 p.m. (ET). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has 0.90% insider ownership while its institutional ownership stands at 68.30%. In last trading activity company’s stock closed at $6.64.

Biotech Stocks Touched New Lows: Actinium Pharmaceuticals (NYSEMKT:ATNM), Oncothyreon Inc (NASDAQ:ONTY), TRACON Pharmaceuticals (NASDAQ:TCON), Enzymotec (NASDAQ:ENZY), Cleveland BioLabs (NASDAQ:CBLI)

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company’s common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued separately. On Friday shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) closed at $3.77.

Oncothyreon Inc. (NASDAQ:ONTY) announced the pricing of previously announced concurrent but separate underwritten offerings of 13,500,000 shares of its Common Stock at a price to the public of $1.50 per share, for expected gross proceeds of approximately $20 million and 1,333 shares of its Series B Convertible Preferred Stock at a price to the public of $1,500 per share, for expected gross proceeds of approximately $2 million. Oncothyreon Inc (NASDAQ:ONTY) in last trading activity moved down -4.46% to close at $1.50. Company weekly performance is -5.06% while its quarterly performance stands at -11.76%. Oncothyreon Inc (NASDAQ:ONTY) is -63.24% away from its 52 week high.

On 29 January, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) raised $36 million by offering 3.6 million shares at $10, well below the $12 to $14 range. On last trading day TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) moved down -0.43% to close at $9.29.

On 3 February, Enzymotec Ltd. (NASDAQ:ENZY) announced that the Australian Patent Office has issued a favorable response to the Company’s request for re-examination of Neptune Technologies & Bioressources’ (“Neptune”) patent as it relates to krill oil in Australia.Enzymotec Ltd. (NASDAQ:ENZY) institutional ownership stands at 60.90%. In last trading activity company’s stock closed at $6.18.

On 4 February, Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. On last trading day Cleveland BioLabs, Inc. (NASDAQ:CBLI) increased 0.32% to close at $3.16. Its volatility for the week is 9.56% while volatility for the month is 15.75%. CBLI’s sales growth for past 5 years was 12.60% and its EPS growth for past 5 years was 19.40%. Cleveland BioLabs, Inc. (NASDAQ:CBLI) monthly performance is -47.33%.

Biotech Stocks Touched New Highs: Cambrex Corporation. (NYSE:CBM), Biogen Idec Inc. (NASDAQ:BIIB), Coherus Biosciences (NASDAQ:CHRS), ImmuCell (NASDAQ:ICCC), Esperion Therapeutics (NASDAQ:ESPR)

Cambrex Corporation. (NYSE:CBM) reported Fourth quarter 2014 sales increased 25% to $128.8 million from $103.0 million in the same period last year. Full year 2014 sales increased 18%, and 19% excluding the impact of foreign currency. On Friday shares of Cambrex Corporation. (NYSE:CBM) closed at $30.01. Company’s sales growth for last 5 years was 5.00% and EPS growth for next 5 years is recorded as 21.00%.

On 29 January, Biotech company, Biogen Idec (NASDAQ:BIIB), reported fourth quarter 2014 earnings per share of $4.08 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $3.74 and the year-ago earnings of $2.33 per share.Biogen Idec Inc. (NASDAQ:BIIB) in last trading activity increased 0.05% to close at $402.00. Company weekly performance is 3.30% while its quarterly performance stands at 25.80%. Biogen Idec Inc. (NASDAQ:BIIB) is -0.10% away from its 52 week high.

Coherus BioSciences, Inc. (NASDAQ:CHRS), announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. On last trading day Coherus Biosciences, Inc. (NASDAQ:CHRS) increased 17.51% to close at $28.66. Its volatility for the week is 11.18% while volatility for the month is 9.98%. CHRS’s EPS growth for past 5 years was -44.33%. Coherus Biosciences, Inc. (NASDAQ:CHRS) monthly performance is 44.82%.

ImmuCell Corporation (NASDAQ: ICCC), will report 2014 full year and fourth quarter financial results after the market closes on Wednesday, February 11, 2015. ImmuCell Corp. (NASDAQ:ICCC) has 8.60% insider ownership while its institutional ownership stands at 8.50%. In last trading activity company’s stock closed at $6.55.

On 2 February, Esperion Therapeutics (NASDAQ:ESPR) announced that the FDA has removed the peroxisome proliferator-activated receptor partial clinical hold on ETC-1002. On last trading day Esperion Therapeutics, Inc. (NASDAQ:ESPR) increased 1.47% to close at $59.39. Its volatility for the week is 9.47% while volatility for the month is 8.68%. ESPR’s EPS growth for past 5 years was -29.50%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) monthly performance is 26.17%.

Biotech Losers In Spotlight: TrovaGene (NASDAQ:TROV), Actinium Pharmaceuticals (NYSEMKT:ATNM), Ohr Pharmaceutical (NASDAQ:OHRP), Advaxis (NASDAQ:ADXS), Kite Pharma (NASDAQ:KITE)

Trovagene, Inc. (NASDAQ: TROV), announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. On Friday shares of TrovaGene, Inc. (NASDAQ:TROV) closed at $4.47.

Actinium Pharmaceuticals Inc. (NYSE MKT:ATNM) announced the pricing of an underwritten public offering of an aggregate 4444444 shares of its common stock and warrants to purchase an aggregate of 3333333 shares of the Company’s common stock at a combined price to the public of $4.50. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) in last trading activity decreased -24.45% to close at $3.77. Company weekly performance is -30.06% while its quarterly performance stands at -49.40%. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) is -74.87% away from its 52 week high.

Ohr Pharmaceutical Inc. (NASDAQ:OHRP) is raising $25 million to fund dual pivotal phase III studies of its Lucentis-boosting eye drops, OHR-102 (squalamine), in newly diagnosed patients with wet age-related macular degeneration (AMD). If all goes well, the company could file a new drug application (NDA) by about mid-2017. On last trading day Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) decreased -8.38% to close at $7.00. Its volatility for the week is 9.89% while volatility for the month is 6.69%. OHRP’s EPS growth for past 5 years was -32.60%. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) monthly performance is -16.67%.

On 28 January, Advaxis, Inc. (NASDAQ:ADXS), announced an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology. Advaxis, Inc. (NASDAQ:ADXS) has 4.00% insider ownership while its institutional ownership stands at 31.60%. In last trading activity company’s stock closed at $7.53.

On 3 February, Kite Pharma, Inc., (NASDAQ:KITE), announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. On last trading day Kite Pharma, Inc. (NASDAQ:KITE) decreased -5.28% to close at $60.27. Its volatility for the week is 7.62% while volatility for the month is 10.46%. Kite Pharma, Inc. (NASDAQ:KITE) monthly performance is -15.08%.

Biotech Gainers in Spotlight: Genetic Technologies Limited (NASDAQ:GENE), Cambrex Corporation. (NYSE:CBM), Portola Pharmaceuticals (NASDAQ:PTLA), Coherus Biosciences (NASDAQ:CHRS), Vericel Corporation (NASDAQ:VCEL)

On 29 January, Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. On Friday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.95. Company’s sales growth for last 5 years was -16.50%.

Cambrex Corporation (NYSE:CBM) is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continued growth in demand for the Company’s active pharmaceutical ingredient (API) contract manufacturing capabilities is driving the need for more capacity. Cambrex Corporation. (NYSE:CBM) in last trading activity increased 27.54% to close at $30.01. Company weekly performance is 33.79% while its quarterly performance stands at 30.88%. Cambrex Corporation. (NYSE:CBM) is 22.74% away from its 52 week high.

On 5 February, Portola Pharmaceuticals (NASDAQ:PTLA) announced that the Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study of betrixaban continue as planned without modification based on the successful completion of a pre-specified futility analysis On last trading day Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) increased 12.11% to close at $30.83. Its volatility for the week is 5.70% while volatility for the month is 5.80%. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) monthly performance is 11.50%.

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. Coherus Biosciences, Inc. (NASDAQ:CHRS) has 9.90% insider ownership while its institutional ownership stands at 36.40%. In last trading activity company’s stock closed at $28.66.

On 29 January, Vericel Corporation (NASDAQ:VCEL), announced the completion of patient enrollment in the company’s Phase 2b ixCELL-DCM clinical trial evaluating ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). On last trading day Vericel Corporation (NASDAQ:VCEL) increased 7.41% to close at $3.48. Its volatility for the week is 4.16% while volatility for the month is 3.98%. VCEL’s EPS growth for past 5 years was 17.30%. Vericel Corporation (NASDAQ:VCEL) monthly performance is 16.39%.

Biotech Top Losers: Gilead Sciences Inc. (NASDAQ:GILD), Achillion Pharmaceuticals (NASDAQ:ACHN), Pacific Biosciences of California (NASDAQ:PACB), Celldex Therapeutics (NASDAQ:CLDX), Enanta Pharmaceuticals (NASDAQ:ENTA)

Gilead Sciences Inc. (NASDAQ:GILD) reported Total revenues of $7.3 billion were no comparison to the year-ago figure of $3.1 billion. Quarterly revenues were above the Zacks Consensus Estimate of $6.7 billion. Full-year 2014 revenues increased 122.2% to $24.9 billion, topping the Zacks Consensus Estimate of $24.3 billion. Earnings (including stock-based compensation expenses) increased to $7.91 per share, way above $1.93 per share in the year-ago period. Earnings were also above the Zacks Consensus Estimate of $7.72 per share. On Wednesday shares of Gilead Sciences Inc. (NASDAQ:GILD) closed at $98.43. Company’s sales growth for last 5 years was 16.00% and EPS growth for next 5 years is recorded as 33.42%.

Achillion Pharmaceuticals (NASDAQ:ACHN) CFO Mary Kay Fenton sold 13,125 shares of the stock on the open market in a transaction dated Friday, January 23rd. The shares were sold at an average price of $16.00, for a total transaction of $210,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity decreased -16.90% to close at $12.05. Company weekly performance is -18.64% while its quarterly performance stands at -0.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is -28.57% away from its 52 week high.

Pacific Biosciences of California Inc. (NASDAQ:PACB) on Tuesday reported a loss of $19 million in its fourth quarter. On a per-share basis, the Menlo Park, California-based company said it had a loss of 26 cents. The maker of genetic analysis technology posted revenue of $16.9 million in the period. On last trading day Pacific Biosciences of California, Inc. (NASDAQ:PACB) decreased -18.25% to close at $6.81. Its volatility for the week is 7.73% while volatility for the month is 6.30%. PACB’s sales growth for past 5 years was 99.20% and its EPS growth for past 5 years was -7.70%. Pacific Biosciences of California, Inc. (NASDAQ:PACB) monthly performance is -12.02%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Bristol Myers-Squibb (BMY) on 29 January announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex’s CD27 targeting investigational immune-activating antibody and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab). Celldex Therapeutics, Inc. (NASDAQ:CLDX) has 0.28% insider ownership while its institutional ownership stands at 91.10%. In last trading activity company’s stock closed at $19.12.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), on 2 February announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. On last trading day Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) decreased -8.06% to close at $36.03. Its volatility for the week is 6.76% while volatility for the month is 5.19%. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) monthly performance is -27.82%.